摘要
胰高糖素样肽-1受体激动剂(GLP-1RAs)除具有很强的降糖作用外,也具有很强的心血管保护作用。随着心血管结局研究结果的公布,GLP-1RAs也被证实可显著改善2型糖尿病患者合并动脉粥样硬化性心脏病的远期风险。本共识针对GLP-1RAs药理学、心血管保护机制、循证医学证据、临床应用建议、不良反应及注意事项等临床问题给出具体的推荐意见。
Glucagon like peptide-1 receptor agonists(GLP-1RAs)not only have strong hypoglycemic effects,but also have strong cardiovascular protective effects.With the announcement of cardiovascular outcomes,GLP-1RAs have been proved to improve the long-term risk of type 2 diabetes patients with atherosclerotic heart disease significantly.This consensus provides specific recommendations on clinical issues such as GLP-1RAs pharmacology,cardiovascular protection mechanisms,evidence-based medical evidence,clinical application recommendations,adverse reactions,and precautions.
出处
《临床心血管病杂志》
CAS
北大核心
2023年第9期651-660,共10页
Journal of Clinical Cardiology